Literature DB >> 19479906

Fibromyalgia--pathways and neurotransmitters.

Stephen M Stahl1.   

Abstract

Fibromyalgia is a syndrome of widespread chronic pain associated with sleep disorders, depressed mood, cognitive impairment and fatigue. Its etiology and pharmacopathology are poorly understood but it is thought to result from a dysfunction of central pain processing mechanisms leading to generalised pain sensitisation. Pain perception is the result of a bidirectional process of ascending and descending pathways. Nociceptive input from peripheral afferent neurons is sent via the dorsal horn of the spinal cord to the higher brain centres involved in pain perception. Some descending inhibitory projections to the spinal cord attenuate the nociceptive effects. Numerous neurotransmitters including serotonin, dopamine, noradrenaline and substance P are involved in these processes. In other neuronal pathways in the brain, the same neurotransmitters are involved in mood control, sleep regulation and cognitive function providing a neurochemical substrate for the wide range of symptoms seen in fibromyalgia. Attenuation of neuronal hyperactivity through ligands acting at the alpha2-delta subunits of voltage-dependent calcium channels and increased inhibitory activity of the descending pathways by inhibition of serotonin and noradrenaline reuptake are two mechanisms that are currently exploited by new medication for the treatment of fibromyalgia. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479906     DOI: 10.1002/hup.1029

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  18 in total

1.  A quest for better understanding of biochemical changes in fibromyalgia syndrome.

Authors:  Abbas Ali Mahdi; Ghizal Fatima
Journal:  Indian J Clin Biochem       Date:  2013-11-20

Review 2.  Fibrofog and fibromyalgia: a narrative review and implications for clinical practice.

Authors:  Howard M Kravitz; Robert S Katz
Journal:  Rheumatol Int       Date:  2015-01-13       Impact factor: 2.631

Review 3.  Fibromyalgia and sleep in animal models: a current overview and future directions.

Authors:  Cristina Frange; Camila Hirotsu; Helena Hachul; Paula Araujo; Sergio Tufik; Monica L Andersen
Journal:  Curr Pain Headache Rep       Date:  2014

4.  Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia.

Authors:  Robert H Palmer; Antonia Periclou; Pradeep Banerjee
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

5.  Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.

Authors:  Amanda M Brandow; Nancy J Wandersee; Mahua Dasgupta; Raymond G Hoffmann; Cheryl A Hillery; Cheryl L Stucky; Julie A Panepinto
Journal:  Br J Haematol       Date:  2016-08-19       Impact factor: 6.998

6.  A brain-derived neurotrophic factor polymorphism Val66Met identifies fibromyalgia syndrome subgroup with higher body mass index and C-reactive protein.

Authors:  Yangming Xiao; I Jon Russell; Ya-Guang Liu
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 2.631

Review 7.  Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.

Authors:  Belinda Coronado; Jacob Dunn; Michael A Veronin; Justin P Reinert
Journal:  J Pharm Technol       Date:  2021-04-19

8.  Role and rationale for the use of milnacipran in the management of fibromyalgia.

Authors:  Jay D Kranzler; R Michael Gendreau
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

9.  Postgraduate corner: Continuing medical education: Psychopharmacology.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

10.  Usefulness of milnacipran in treating phantom limb pain.

Authors:  Yasuhide Nagoshi; Akira Watanabe; Saiko Inoue; Tomoki Kuroda; Mitsuo Nakamura; Yoshitake Matsumoto; Kenji Fukui
Journal:  Neuropsychiatr Dis Treat       Date:  2012-11-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.